Abstract library

19 results for "Smith".
#3038 Managing Neuroendocrine Neoplasms (NEN) in Association with HIV Infection: A Single Institution Experience
Introduction: There is a paucity of knowledge regarding NEN and HIV infection in the literature.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Aimee R Hayes
Authors: Hayes A R, Smith K, Liu M, Jenkinson S, ...
#3082 MEN1 Associated pNETs: A Case Series from Two Centres of Excellence in the United Kingdom
Introduction: Literature on MEN1 associated PNETS as a unique clinico-pathological entity is evolving.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Hema Venkataraman
#459 Differential Claudin-1 Gene Expression in Neural Crest-Derived Tumors of Common Embryological Origin
Introduction: Pheochromocytoma and paraganglioma are neural crest-derived tumors originating from chromaffin cells, with the former being intra–adrenal in location, while the latter are extra-adrenal.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Miss Beatrice Philip
Authors: Philip B, Smith R, Lam A, ...
Keywords: Claudin-1
#681 The Use of Capsule Endoscopy for Assessment of Neuroendocrine Tumors of Unknown Primary Tumor Location
Introduction: Recent studies suggest that capsule endoscopy (CE) should be implemented in diagnostic work-up in patients suspected to have small bowel (SB) tumors. SB accounts for the primary tumor site in 80%-85% of patients with intestinal neuroendocrine tumors (NET). In 10%-15% of patients diagnosed with metastasized NET, the primary tumor site remains obscure.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: PhD Panagiotis Drymousis
#857 Video Capsule Endoscopy as a Tool to Detect Small Bowel Neuroendocrine Tumors
Introduction: Recent studies suggest that video capsule endoscopy (CE) should be implemented in diagnostic work-up in patients with suspected small bowel tumors. Small bowel is the primary site in 80%-85% of patients with intestinal neuroendocrine tumors (NET). In 10%-15% of patients diagnosed with metastasized NET, the localization of the primary tumors remains obscure.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Helen Miller
#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)
Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Philippe Ruszniewski
Keywords: PRO
#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study
Introduction: CS associated with NETs can have a negative impact on patients’ QoL.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Philippe Ruszniewski
Keywords: quality of life
#1263 Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
Introduction: 68GaDOTA TATE imaging of patients with neuroendocrine tumours has shown that tumour sequestration is a major factor leading to a sink effect that decreases activity concentration in healthy tissues, particularly the renal parenchyma.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Steven Goodman
Keywords: dosimetry, PRRT
#1351 Sunitinib (SU) in Patients with Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) Results from a Phase III Randomized Study Including Adjustment for Crossover
Introduction: This pivotal, Phase 3, double-blind study of SU in patients (pts) with advanced, progressive pNETs met its primary endpoint with median progression-free survival of 11.4 months (mo) for SU vs 5.5 mo for placebo (PBO; HR=0.42; 95% CI 0.26–0.66; p
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD, PhD Eric Raymond
Keywords: sutent, OS
#1425 Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate.
Introduction: Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Catherine Lucas
Authors: Lucas C, Goodman S, Smith J, Burge M, ...